Main Page

<span class="mwt-editable mwt-comment" id="R1766923378676" " draggable="false" contenteditable="true">Hides title of Main Page

Welcome to Neoplasm.org

Neoplasm.org is a collaborative, open-access knowledge base dedicated to the rapid dissemination of oncology clinical trial results and evidence-based treatment regimens.

Modeled after the collaborative spirit of the medical community, our mission is to translate complex research into actionable clinical insights—free of charge and accessible to everyone, from oncologists and researchers to students and patients.

Guidelines

Solid Tumors

Hematological Neoplasms

Solid Tumors
Breast Oncology
Early breast cancer (EBC)
EBC, NOS	HR-positive EBC	HER2-positive EBC	HER2-low EBC
HR-positive and HER2-positive EBC	Early triple-negative breast cancer (eTNBC)
Metastatic breast cancer (MBC)
MBC, NOS	HR-positive MBC	HER2-positive MBC	HER2-low MBC
HR-positive and HER2-positive MBC	Metastatic triple-negative breast cancer (mTNBC)	CNS metastases
Breast cancer with molecular alterations
Testfdasfjifojifjo	PI3K pathway-altered Breast cancer
Dermatologic Oncology
Melanoma
Melanoma, NOS	BRAF-mutated Melanoma	KIT-mutated Melanoma	NRAS-mutated Melanoma
Uveal melanoma
Non-melanoma skin cancer (NMSC)
Cutaneous BCC	Cutaneous SCC	Merkel cell carcinoma (MCC)
Endocrine Oncology
Other endocrine cancers
Adrenocortical carcinoma	Neuroendocrine tumor (NET)	Neuroendocrine carcinoma (NEC)	Pancreatic NET
Pheochromocytoma
Thyroid cancer without molecular alterations
Thyroid cancer, NOS	Anaplastic thyroid cancer (ATC)	Differentiated thyroid cancer (DTC)	Medullary thyroid cancer (MTC)
Thyroid cancer with molecular alterations
BRAF-mutated Thyroid cancer	RET-positive Thyroid cancer
Gastrointestinal Oncology
Upper GI tract
Esophageal cancer, NOS	Esophageal adenocarcinoma	Esophageal squamous cell carcinoma (ESCC)	Gastric cancer, NOS
HER2-positive gastric cancer
Lower GI tract
Anal cancer	Appendiceal tumor	Colon cancer, NOS	RAS wild-type colon cancer
Colorectal cancer (CRC), NOS	BRAF-mutated CRC	HER2-positive CRC	MSI-H or dMMR CRC
RAS wild-type CRC	Rectal cancer	Small bowel adenocarcinoma
Hepatobiliary cancer
Biliary tract cancer	Cholangiocarcinoma	Gallbladder cancer	Hepatocellular carcinoma (HCC)
Periampullary adenocarcinoma
Pancreatic cancer
Pancreatic adenocarcinoma, NOS	BRCA-mutated Pancreatic adenocarcinoma	NRG1-positive Pancreatic adenocarcinoma	Pancreatic NET
Genitourinary Oncology
Kidney cancer
Renal cell carcinoma (RCC), NOS	Clear cell RCC (ccRCC)	Non-clear cell RCC (nccRCC)	Papillary RCC
Sarcomatoid RCC	VHL-associated RCC
Male genital tract
Penile cancer	Prostate cancer, NOS	Prostate cancer, HRD-positive	Testicular cancer
Urinary tract cancer
Urothelial carcinoma, NOS	Bladder cancer	Upper tract urothelial carcinoma (UTUC)
Gynecologic Oncology
Ovarian cancer
High-grade serous ovarian cancer (HGSOC)	Low-grade serous ovarian cancer (LGSOC)	Ovarian cancer, BRCA-mutated
Other gynecologic cancer
Cervical cancer	Endometrial cancer	Gestational trophoblastic neoplasia	Vulvar cancer
Head & Neck Oncology
Head and neck cancer	Nasopharyngeal carcinoma (NPC)	HPV+ Oropharyngeal cancer
Mesothelioma
Malignant peritoneal mesothelioma (MPEM)		Malignant pleural mesothelioma (MPM)
Neuro-Oncology
Primary central nervous system (CNS) malignancies
Anaplastic glioma	Craniopharyngioma	Diffuse midline glioma New	Glioblastoma (GBM)
Low-grade glioma	Meningioma	Subependymal giant cell astrocytoma (SEGA)
Secondary CNS malignancies
CNS carcinoma	CNS leukemia	CNS lymphoma	CNS melanoma
Sarcoma
Bone sarcoma
Bone sarcoma, NOS	Ewing sarcoma	Giant-cell tumor of bone	Osteosarcoma
Soft tissue sarcoma
Soft tissue sarcoma (STS), NOS	Alveolar soft part sarcoma (ASPS)	Dermatofibrosarcoma protuberans	Desmoid tumor
Epithelioid sarcoma	Gastrointestinal stromal tumor (GIST)	Inflammatory myofibroblastic tumor (IMT)	Leiomyosarcoma (LMS)
Liposarcoma	PEComa	Rhabdomyosarcoma (RMS)	Tenosynovial giant cell tumor (TGCT)
Vascular sarcoma
Vascular sarcoma, NOS	Angiosarcoma	Kaposi sarcoma (KS)
Thoracic Oncology
Non-small cell lung cancer (NSCLC) without driver alterations
NSCLC, NOS	Nonsquamous NSCLC	Squamous NSCLC	PD-L1-positive NSCLC
CNS metastases
NSCLC with driver alterations
ALK-positive NSCLC	BRAF-mutated NSCLC	c-Met-positive NSCLC	EGFR-mutated NSCLC
HER2-mutated NSCLC	KRAS-mutated NSCLC	MET-mutated NSCLC	NRG1-positive NSCLC
RET-positive NSCLC	ROS1-positive NSCLC
Other thoracic cancer
Malignant pleural mesothelioma (MPM)	Small cell lung cancer (SCLC)	Thymoma
Site-agnostic
BRAF	EGFR	ERBB2 (HER2)	ERBB3 (HER3)
MSI-H or dMMR	NTRK	RET	SMO or PTCH-1 (Hedgehog)
TMB-H	Carcinoma of unknown primary (CUP)

Malignant Hematology
Acute leukemias
Acute leukemia, KMT2A-rearranged	Acute myeloid leukemia (AML)	AML, FLT3-positive	AML, IDH-mutated
AML, NPM1-mutated	Acute promyelocytic leukemia (APL)	B-cell acute lymphoblastic leukemia (B-ALL)	B-ALL, Ph+
T-cell acute lymphoblastic leukemia (T-ALL)	Blastic plasmacytoid dendritic cell neoplasm (BPDCN)	CNS leukemia
Myeloproliferative neoplasms and myelodysplastic syndromes
Chronic myeloid leukemia (CML)	Chronic myelomonocytic leukemia (CMML)	Essential thrombocythemia (ET)	Hypereosinophilic syndrome (HES)
Myelodysplastic syndrome (MDS)	Primary & secondary myelofibrosis (PMF/SMF)	Myeloproliferative neoplasm, accelerated phase (MPN-AP) New	Polycythemia vera (PV)
Systemic mastocytosis
Aggressive lymphomas
Burkitt lymphoma (BL) or Burkitt-like lymphoma	Classical Hodgkin lymphoma (cHL)	CNS lymphoma	Diffuse large B-cell lymphoma (DLBCL)
Gastric DLBCL New	High-grade B-cell lymphoma (HGBL)	HIV-associated lymphoma	Mantle cell lymphoma (MCL)
Mediastinal gray-zone lymphoma (MGZL)	Primary mediastinal B-cell lymphoma (PMBL)	Transformed lymphoma (TL)
Indolent lymphomas
Chronic lymphocytic leukemia (CLL/SLL)	Follicular lymphoma (FL)	Hairy cell leukemia (HCL)	Hodgkin lymphoma, nodular lymphocyte-predominant (NLP-HL)
Indolent lymphoma (iNHL)	MALT lymphoma	Marginal zone lymphoma (MZL)	Waldenström macroglobulinemia (WM/LPL)
Plasma cell dyscrasias
Light-chain (AL) amyloidosis	Multiple myeloma (main page)	MM, induction	MM, consolidation & maintenance
MM, relapsed/refractory	Plasma cell leukemia (PCL)	POEMS syndrome	Smoldering multiple myeloma (SMM)
T-cell and NK-cell neoplasms
Adult T-cell leukemia-lymphoma (ATLL)	Anaplastic large cell lymphoma (ALCL)	Cutaneous T-cell lymphoma (CTCL)	Extranodal NK- and T-cell lymphoma, nasal type (ENKTCL-NT
Large granular lymphocytic (LGL) leukemia	NK- and T-cell lymphoma (NKTCL)	Peripheral T-cell Lymphoma (PTCL)	T-cell acute lymphoblastic lymphoma (T-LBL)
T-cell prolymphocytic lymphoma (T-PLL)
Lymphoproliferative disorders
Castleman disease		Post-transplant lymphoproliferative disorder (PTLD)
Histiocytic disorders
Erdheim-Chester disease (ECD)	Hemophagocytic lymphohistiocytosis (HLH)	Langerhans cell histiocytosis (LCH)	Rosai-Dorfman-Destombes disease

Pediatric Neoplasms
Pediatric CNS malignancies
Low-grade glioma	High-grade glioma	Medulloblastoma
Pediatric hematologic neoplasms
B-cell acute lymphoblastic leukemia (B-ALL)	B-ALL, Ph+	T-cell acute lymphoblastic leukemia (T-ALL)	Acute myeloid leukemia (AML)
Anaplastic large cell lymphoma (ALCL)	Chronic myeloid leukemia (CML)	Juvenile myelomonocytic leukemia (JMML)
Classical Hodgkin lymphoma (cHL)	Non-Hodgkin lymphoma (NHL)
Pediatric solid tumors
Epithelioid sarcoma	Ewing sarcoma	Hepatoblastoma	Neuroblastoma
Osteosarcoma	Retinoblastoma	Rhabdomyosarcoma	Wilms tumor

Transplant and Immune Effector Cells (IECs)
Stem cell mobilization	Allogeneic HSCT	Autologous HSCT	Chimeric antigen receptor T cells (CAR-T)
Graft versus host disease (GVHD)	Hepatic veno-occlusive disease (VOD/SOS)

Classical Hematology
Hemostasis and thrombosis
Acquired coagulopathy	Acquired thrombotic thrombocytopenic purpura (aTTP)	Antiphospholipid antibody syndrome (APLAS)	Congenital thrombotic thrombocytopenic purpura (cTTP)
Hemophilia A	Hemophilia B	Heparin-induced thrombocytopenia (HIT)	Hereditary hemorrhagic telangiectasia (HHT)
Inherited thrombophilia	Thrombotic microangiopathy (TMA)	Venous thromboembolism (VTE)	von Willebrand disease (vWD)
Cytopenias
Aplastic anemia	Autoimmune cytopenia	Immune thrombocytopenia (ITP)	Thrombocytopenia in liver disease
WHIM syndrome
Hemolytic disorders and Hemoglobinopathies
Atypical hemolytic uremic syndrome (aHUS)	Warm autoimmune hemolytic anemia (WAIHA)	Cold agglutinin disease (CAD)	Paroxysmal nocturnal hemoglobinuria (PNH)
Pyruvate kinase deficiency (PKD)	Beta thalassemia	Sickle cell disease (SCD)

Browse our complete index of pages

What We Do

In the fast-moving field of oncology, keeping up with the latest data is a challenge. Neoplasm.org serves as a "living textbook" where:

• Clinical Trial Results are summarized and categorized for quick reference.

• Treatment Regimens are detailed with evidence-backed citations and toxicity profiles.

• Collaborative Note-taking allows experts to contribute clinical pearls and real-world experience.

Why Neoplasm.org?

Unlike static journals, our platform is built for speed and collaboration. Using modern collaborative tools (powered by Docmost), we allow credentialed contributors to update notes in real-time as new data emerges from ASCO, ESMO, and major journals.

• Free to the Public: Information that saves lives should not be behind a paywall.

• Clinically Structured: Organized by disease site, histology, and stage for maximum utility during rounds or tumor boards.

• Evidence-Based: Every note is rooted in published clinical evidence.

Join the Collaboration

Neoplasm.org is built by the oncology community, for the oncology community. Whether you are adding a new regimen or refining a trial summary, your contributions help build a more transparent and informed world for cancer care.

Disclaimer: Neoplasm.org is an educational and research resource. Clinical decisions should always be made by a qualified healthcare professional.